14504-07-5

Basic information

• Product Name: 2-Acetyl-4-methylsalicylicacid
• Synonyms: 2-Acetoxy-4-methylbenzoicacid;2-Acetyl-4-methylsalicylicacid;O-ACETYL-4-METHYLSALICYLIC ACID;Benzoic acid, 2-(acetyloxy)-4-Methyl-;2-(Acetyloxy)-4-methylbenzoic acid
• CAS NO: 14504-07-5
• Molecular Formula: C₁₀H₁₀O₄
• Molecular Weight: 194.184
• Mol File: 14504-07-5.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Density: 1.245
• CAS DataBase Reference: 2-Acetyl-4-methylsalicylicacid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Acetyl-4-methylsalicylicacid(14504-07-5)
• EPA Substance Registry System: 2-Acetyl-4-methylsalicylicacid(14504-07-5)

Safety Data

• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• Hazardous Substances Data: 14504-07-5(Hazardous Substances Data)

Usage

General Description

2-Acetyl-4-methylsalicylic acid, also known as amacetamol, is a chemical compound that belongs to the class of aromatic compounds. It is commonly used as an intermediate in the synthesis of other organic compounds and in the production of pharmaceuticals. This chemical is derived from the acetylation of 4-methylsalicylic acid, and it has a wide range of applications in the pharmaceutical industry, including as an analgesic and antipyretic agent. It is also used in the treatment of pain, fever, and inflammation. 2-Acetyl-4-methylsalicylic acid has a molecular weight of 206.228 g/mol and is a white crystalline powder.

Upstream product

• 50-85-1 2-hydroxy-p-toluic acid 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 1590343-09-1 4-amino-2-imino-8-methyl-1,2-dihydro-5H-chromeno[2,3-d]pyrimidin-5-one 
• 1375074-75-1 4-imino-8-methyl-3-phenyl-2-thioxo-1,2,3,4-tetrahydro-5H-chromeno[2,3-d]pyrimidine-5-one 
• 1237514-75-8 2-(2-hydroxy-4-methylbenzamido)-4-phenylbenzoic acid 
• 1237519-25-3 methyl 2-(2-acetoxy-4-methylbenzamido)-4-phenylbenzoate 
• 13515-12-3 methyl 2-acetoxy-4-methylbenzoate 
• 49667-22-3 2-hydroxy-4-methylbenzamide 
• 57148-35-3 2-acetoxy-4-methyl-benzoyl chloride 
• 99601-62-4 C₂₂H₃₆NO₃P 

Relevant articles and documents

Development of methylated cobalt–alkyne complexes with selective cytotoxicity against COX-positive cancer cell lines

Derivatives of the cytotoxic cyclooxygenase (COX) inhibitor [(prop-2-ynyl)?2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS) with a methyl group in the 3, 4, 5, or 6 position of the acetylsalicylic acid (ASS) scaffold were synthesized with the aim to achieve enhanced selectivity for COX-2. From this modification, a higher specificity for COX-2-expressing tumors is expected, preventing COX-1-mediated side effects. The cobalt–alkyne complexes were tested for their COX-inhibitory and antiproliferative properties as well as their cellular uptake. Methylation reduced the effects at the isolated COX-1, whereas those at the isolated COX-2 remained nearly constant compared to Co-ASS. In cellular systems, the new compounds showed superior cytotoxicity toward the COX-positive HT-29 colon carcinoma cells than cisplatin. The reduced growth-inhibitory potency in T-24 cells, which express distinctly fewer COX enzymes (COX-1/COX-2 = 50/1) than HT-29 cells (COX-1/COX-2 = 50/50), and the only marginal activity in COX-negative MCF-7 breast cancer cells point to an interference in the arachidonic acid cascade through COX-2 inhibition as part of the mode of action, especially as the cellular uptake was even higher in MCF-7 cells than in T-24 cells. These findings clearly demonstrate that the methylated cobalt–alkyne complexes possess promising potential for further development as reasonable alternatives to the limited platinum-based antitumor agents.

COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES

The present invention refers to compounds of formula: (formula A), wherein R1 is selected from (formula I), (formula II), (formula (III), (formula IV), (formula V), or (formula B), and wherein R2, R3, R4 and Rs

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.